丽珠医药(01513)：重组新型冠状病毒融合蛋白二价(原型株/Omicron XBB变异株)疫苗(CHO细胞)被纳入紧急使用
丽珠医药(01513)发布公告，2023年12月1日，公司控股附属公司珠海市丽珠单抗生物技术有限公司(丽珠单抗)收到国家相关部门的函件，丽珠单抗研发生产的重组新型冠状病毒融合蛋白二价(原型株/Omicron XBB 变异株)疫苗(CHO 细胞)经国家卫生健康委提出建议，国家药品监督管理局组织论证同意纳入紧急使用。本品是继重组新型冠状病毒融合蛋白疫苗(丽康 V-01)之后，公司第二款被国家纳入紧急使用的新冠疫苗产品。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.